Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular DegenerationGlobeNewsWire • 09/14/22
Adverum Biotechnologies to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/08/22
Adverum to Present at the Inaugural Gilmartin Group Emerging Growth Company ShowcaseGlobeNewsWire • 08/26/22
Adverum Biotechnologies to Participate in the 2nd Annual H.C. Wainwright Ophthalmology Virtual ConferenceGlobeNewsWire • 08/10/22
Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMDGlobeNewsWire • 07/15/22
Adverum Biotechnologies Completes IND Amendment and Prepares to Initiate the Phase 2 LUNA Trial of ADVM-022 in Wet AMDGlobeNewsWire • 07/06/22
Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMDGlobeNewsWire • 06/24/22
Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After a Single IVT Injection of ADVM-022 in the OPTIC Study in Wet AMDGlobeNewsWire • 06/09/22
Adverum Biotechnologies Announces New Data at the Macula Society's 2022 Annual MeetingGlobeNewsWire • 06/02/22
Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene TherapyGlobeNewsWire • 05/19/22
Adverum Presents Data at ASGCT Further Supporting Phase 2 Development Plans for ADVM-022GlobeNewsWire • 05/17/22
Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual MeetingGlobeNewsWire • 05/01/22
Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDAGlobeNewsWire • 04/06/22
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 03/29/22